Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial.

Authors : De Caluwe A, Buisseret L, Poortmans P, Van Gestel D, Salgado R, Sotiriou C, Larsimont D, Paesmans M, Craciun L, Drisis S, Vandekerckhove C, Reyal F, Veys I, Eiger D, Piccart-Gebhart M, Romano E, Ignatiadis M
Year : 2021
Journal : BMC Cancer
Volume : 21
Pages : 899

Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy.

Authors : Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA Jr, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Borrego MR, Moore HC, Saunders C, Cardoso F, Susnjar S, Bjelic-Radisic V, Smith KL, Piccart-Gebhart M, Korde LA, Goldhirsch A, Gelber Rd, Pagani O
Year : 2021
Journal : Breast
Volume : 59
Pages : 327-338

Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial.

Authors : Venet D, Rediti M, Maetens M, Fumagalli D, Brown DN, Majjaj S, Salgado R, Pusztai L, Harbeck N, El-Abed S, Wang Y, Saura C, Gomez H, Semiglazov VF, de Azambuja E, Huober J, Nuciforo P, Di Cosimo S, Piccart-Gebhart M, Loi S, Rothé F, Sotiriou C
Year : 2021
Journal : Clin Cancer Res
Volume : 27
Pages : 5607-5618

Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations.

Authors : Conforti F, Pala L, Pagan E, Rocco EG, Bagnardi V, Montagna E, Peruzzotti G, De Pas T, Fumagalli C, Pileggi S, Pesenti C, Marchini S, Corso G, Marchio C, Sapino A, Graffeo R, Collet L, Aftimos P, Sotiriou C, Piccart-Gebhart M, Gelber Rd, Viale G, Colleoni M, Goldhirsch A
Year : 2021
Journal : Breast
Volume : 59
Pages : 94-101

HER2-Low Breast Cancer: Molecular Characteristics and Prognosis.

Authors : Agostinetto E, Rediti M, Piccart-Gebhart M, Fimereli D, Debien V, Aftimos P, Sotiriou C, de Azambuja E
Year : 2021
Journal : Cancers (Basel)
Volume : 13

Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge.

Authors : Jackisch C, Cortazar P, Geyer CE Jr, Gianni L, Gligorov J, Machackova Z, Perez EA, Schneeweiss A, Tolaney SM, Untch M, Wardley A, Piccart-Gebhart M
Year : 2021
Journal : Cancer Treat Rev
Volume : 99
Pages : 102229

Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust.

Authors : Piccart-Gebhart M, Kalinsky K, Gray R, Barlow WE, Poncet C, Cardoso F, Winer E, Sparano J
Year : 2021
Journal : Ann Oncol
Volume : 32
Pages : 1077-1082

Adjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast Cancer.

Authors : Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber Rd, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart-Gebhart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, Mcfadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr
Year : 2021
Journal : N Engl J Med
Volume : 384
Pages : 2394-2405

Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial.

Authors : Martel S, Lambertini M, Agbor-Tarh D, Ponde NF, Gombos A, Paterson V, Hilbers F, Korde L, Manukyants A, Dueck A, Maurer C, Piccart-Gebhart M, Moreno-Aspitia A, Desmedt C, Di Cosimo S, de Azambuja E
Year : 2021
Journal : J Natl Compr Canc Netw
Volume : 19
Pages : 181-189

Impact of HIV infection on baseline characteristics and survival of women with breast cancer.

Authors : Brandão M, Bruzzone M, Franzoi MA, de Angelis C, Eiger D, Caparica R, Piccart-Gebhart M, Buisseret L, Ceppi M, Dauby N, Carrilho C, Lunet N, de Azambuja E, Lambertini M
Year : 2021
Journal : AIDS
Volume : 35
Pages : 605-618

Survival Impact and Cost-Effectiveness of a Multidisciplinary Tumor Board for Breast Cancer in Mozambique, Sub-Saharan Africa.

Authors : Brandão M, Guisseve A, Bata G, Firmino-Machado J, Alberto M, Ferro J, Garcia C, Zaqueu C, Jamisse A, Lorenzoni C, Piccart-Gebhart M, Leitão D, Come J, Soares O, Gudo-Morais A, Schmitt F, Tulsidás S, Carrilho C, Lunet N
Year : 2021
Journal : Oncologist
Volume : 26
Pages : e996-e1008

Immunotherapy for early breast cancer: too soon, too superficial, or just right?

Authors : Franzoi MA, Romano E, Piccart-Gebhart M
Year : 2021
Journal : Ann Oncol
Volume : 32
Pages : 323-336

Tolerability and toxicity of trastuzumab or trastuzumab?+?lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D).

Authors : Pondé N, Agbor-Tarh D, Dal Lago L, Korde LA, Hilbers F, Jackisch C, Werner O, Gelber Rd, Jatoi A, Dueck AC, Moreno-Aspitia A, Sotiriou C, de Azambuja E, Piccart-Gebhart M
Year : 2021
Journal : Breast Cancer Res Treat
Volume : 185
Pages : 107-116

Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy.

Authors : Franzoi MA, Eiger D, Ameye L, Ponde N, Caparica R, de Angelis C, Brandão M, Desmedt C, Di Cosimo S, Kotecki N, Lambertini M, Awada A, Piccart-Gebhart M, Azambuja E
Year : 2021
Journal : J Natl Cancer Inst
Volume : 113
Pages : 462-470

STAT3 activation in HER2-positive breast cancers: Analysis of data from a large prospective trial.

Authors : Sonnenblick A, Agbor-Tarh D, de Azambuja E, Hultsch S, Izquierdo M, Liu M, Pruneri G, Harbeck N, Piccart-Gebhart M, Moreno-Aspita A, Granit RZ, Rouas G, Fahoum I, Sotiriou C
Year : 2021
Journal : Int J Cancer
Volume : 148
Pages : 1529-1535

Association between the histopathological growth patterns of liver metastases and survival after hepatic surgery in breast cancer patients.

Authors : Bohlok A, Vermeulen P, Leduc S, Latacz E, Botzenhart L, Richard F, De Schepper M, Geukens T, Lucidi V, Ignatiadis M, Aftimos P, Sotiriou C, Piccart-Gebhart M, Hendlisz A, Van Laere S, Dirix L, Noël JC, Biganzoli E, Larsimont D, Desmedt C, Donckier V
Year : 2020
Journal : NPJ Breast Cancer
Volume : 6
Pages : 64

Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial.

Authors : de Angelis C, Ignatiadis M, Piccart-Gebhart M
Year : 2020
Journal : Ann Transl Med
Volume : 8
Pages : 1338

Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells.

Authors : Gómez-Aleza C, Nguyen B, Yoldi G, Ciscar M, Barranco A, Hernández-Jiménez E, Maetens M, Salgado R, Zafeiroglou M, Pellegrini P, Venet D, Garaud S, Trinidad EM, Benítez S, Vuylsteke P, Polastro L, Wildiers H, Simon P, Lindeman G, Larsimont D, Van den Eynden G, Velghe C, Rothé F, Willard-Gallo K, Michiels S, Muñoz P, Walzer T, Planelles L, Penninger J, Azim HA Jr, Loi S, Piccart-Gebhart M, Sotiriou C, González-Suárez E
Year : 2020
Journal : Nat Commun
Volume : 11
Pages : 6335

Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial.

Authors : Di Cosimo S, Porcu L, Agbor-Tarh D, Cinieri S, Franzoi MA, De Santis MC, Saura C, Huober J, Fumagalli D, Izquierdo M, Piccart-Gebhart M, Daidone MG, de Azambuja E
Year : 2020
Journal : Breast Cancer Res
Volume : 22
Pages : 115

Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors.

Authors : Piccart-Gebhart M, Hilbers FS, Bliss JM, Caballero C, Frank ES, Renault P, Naït Kaoudjt R, Schumacher E, Spears PA, Regan MM, Gelber Rd, Davidson NE, Norton L, Winer EP
Year : 2020
Journal : J Clin Oncol
Volume : 38
Pages : 4120-4129